Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Crimean Congo Hemorrhagic Fever

Interventions

BIOLOGICAL

N-pVAX1

Crimean Congo Hemorrhagic Fever Vaccine

Trial Locations (1)

RECRUITING

Phase I Unit, Karolinska University Hospital, Stockholm

All Listed Sponsors

lead

Karolinska Institutet

OTHER